Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 3/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5887358 | 0.86 | MAPT (0.42) | MAPK14PTGER1MAPK8 | |
| SCHEMBL5887000 | 0.85 | PPARG (0.40) | MAPK14KLKB1PPARGNAMPTMAPK8 | |
| SCHEMBL5887321 | 0.85 | RXFP1 (0.40) | MAPK14KLKB1PPARGNAMPT | |
| SCHEMBL5886931 | 0.84 | MAPK8 (0.41) | MAPK14PPARGMAPK8 | |
| SCHEMBL5886862 | 0.84 | MAPK8 (0.40) | MAPK8 | |
| SCHEMBL5886854 | 0.84 | SMN1; SMN2 (0.43) | — | |
| SCHEMBL5886696 | 0.84 | EPHX2 (0.41) | MAPK14KLKB1PPARGNAMPTPDE10A | |
| SCHEMBL5887103 | 0.83 | MAPK14 (0.35) | MAPK14MAPK8 | |
| SCHEMBL5886787 | 0.82 | RORC (0.41) | MAPK8PDE4B | |
| SCHEMBL5887454 | 0.80 | PDE4B (0.38) | MAPK14MAPK8PDE4BPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | claimed |
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | PHARMACIA ITALIA S.P.A. | 2004-01-15 | — | — | US | claimed |
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | TERT, TERF2, TERF2IP | MAPK14 1051/4885KLKB1 3931/4885PPARG 3749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.